Evidence map›Paper›PMID 42688902›Full record

ArticleJBMR plus2026

Generation of

Ines Foessl, Yuan Guo, Rosinda Mies, Moustapha Kassem, Johannes P T M van Leeuwen, Bram C J van der Eerden, Barbara Obermayer-Pietsch, Jeroen van de Peppel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ines FoesslDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria.ORCID https://orcid.org/0000-0002-9804-8859
Yuan GuoDepartment of Internal Medicine, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.ORCID https://orcid.org/0009-0003-6996-545X
Rosinda MiesDepartment of Internal Medicine, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.ORCID https://orcid.org/0009-0000-9972-2270
Moustapha KassemDepartment of Molecular Endocrinology, University of Southern Denmark and Odense University Hospital, 5000 Odense, Denmark.ORCID https://orcid.org/0000-0003-1557-0869
Johannes P T M van LeeuwenDepartment of Internal Medicine, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-2282-4006
Bram C J van der EerdenDepartment of Internal Medicine, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-4403-6497
Barbara Obermayer-PietschDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria.ORCID https://orcid.org/0000-0003-3543-1807
Jeroen van de PeppelDepartment of Internal Medicine, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-6524-727X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human bone marrow-derived stromal cells (hMSCs) are a great resource for studying how genes influence cell fate and differentiation into various cell types like osteoblasts, adipocytes, and chondrocytes, among other cell types. However, genetic manipulation of primary hMSCs has been challenging due to their short lifespan and cellular senescence after limited passaging. Their low and unstable transfection efficiency also complicates gene delivery or inactivation, hindering long-term functional studies. The limited lifespan has been effectively solved by immortalizing hMSCs with telomerase reverse transcriptase (hMSCs-TERT). The use of these cells is ideal for functional studies of osteoblast and adipocyte differentiation through genetic manipulation, providing a stable and reliable model. Here, we have engineered a stable CAS9 expressing hMSC-TERT cell line (hMSC-TERT

Indexed as

CRISPR-Cas9differentiationdisease modelinggene inactivationhMSC-TERTCAS9 gene editingosteoblastsstem cell research

Identifiers

PMID42688902
PMCPMC13537448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.